Skip to main content
Esteban Martinez, MD, Emergency Medicine, Opelousas, LA

EstebanAlbertoMartinezMD

Emergency Medicine Opelousas, LA

Physician

Are you Dr. Martinez?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 36 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    3983 I 49 S Service Rd
    Opelousas, LA 70570
    Phone+1 337-942-2922

Summary

  • Dr. Esteban Martinez, MD is an emergency medicine physician in Opelousas, Louisiana. He is currently licensed to practice medicine in Louisiana and Florida.

Education & Training

  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemFellowship, Nephrology, 1984 - 1986
  • Rutgers Health/Jersey City Medical Center
    Rutgers Health/Jersey City Medical CenterResidency, Internal Medicine, 1981 - 1984
  • Universidad Central del Este Facultad de Medicina
    Universidad Central del Este Facultad de MedicinaClass of 1980

Certifications & Licensure

  • LA State Medical License
    LA State Medical License 1992 - 2015
  • FL State Medical License
    FL State Medical License 1983 - 2012

Publications & Presentations

PubMed

Press Mentions

  • European Commission Approves Merck’s DELSTRIGO™ (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (Doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropr...
    European Commission Approves Merck’s DELSTRIGO™ (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (Doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropr...November 28th, 2018
  • Cardiovascular Risk Unclear for HIV Patients on Dolutegravir
    Cardiovascular Risk Unclear for HIV Patients on DolutegravirOctober 30th, 2018

Professional Memberships